Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly's Prices After Concessions Rise 6% In 2017, While Merck's Net Prices Decline

Executive Summary

Price transparency reports from the big pharmas also show continued increases in price concessions in 2017, but a slow-down in list price increases.

Advertisement

Related Content

Merck's New Pricing Pledge Shows Style Over Substance
A US Drug Pricing Rebellion Looms, Analyst Says
A US Drug Pricing Rebellion Looms, Analyst Says
Which Pharma Firm Increases US Prices The Most?
Where Will It End? Lilly’s US Price Concessions Increase 30% In 2016
Janssen's Drug Pricing Report Emphasizes Value Of Rebates

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100705

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel